Use of lipid-modulating drugs in complicated course of coronary heart disease.
We present the results of the study of lipid-modulating drugs (pravastatin, atorvastatin, simvastatin, and fibrate gemfibrozil) in complicated coronary heart disease (acute coronary syndrome without ST elevation, chronic heart failure. In acute coronary syndrome statins produced a positive effect on some studied parameters, while in heart failure only the safety of short-term therapy with statins was demonstrated.
Gratsianskii
N A
NA
Laboratory of Clinical Cardiology, Institute of Physicochemical Medicine, Federal Agency on Health Care and Social Development, Moscow.
Vaulin
N A
NA
D000990:Antithrombin III / Q000378:metabolism; D000069059:Atorvastatin; D008078:Cholesterol, LDL / Q000378:metabolism; D003327:Coronary Disease / Q000188:drug therapy*; D004452:Echocardiography; D005260:Female; D015248:Gemfibrozil / Q000627:therapeutic use; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D010447:Peptide Hydrolases / Q000378:metabolism; D017035:Pravastatin / Q000627:therapeutic use; D011516:Prothrombin / Q000378:metabolism; D011758:Pyrroles / Q000627:therapeutic use; D019821:Simvastatin / Q000627:therapeutic use; D014841:von Willebrand Factor / Q000378:metabolism
D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D011758:Pyrroles; C046193:antithrombin III-protease complex; D014841:von Willebrand Factor; D000990:Antithrombin III; D011516:Prothrombin; D000069059:Atorvastatin; D019821:Simvastatin; D010447:Peptide Hydrolases; D017035:Pravastatin; D015248:Gemfibrozil